{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6Y9MoIDA","lastupdate":"2022-12-14T00:00:00.000Z","update_date":"2022-12-14T00:00:00.000Z","lastModified":"May 25, 2025","active":1,"confidence_score":97,"confidence_score_reason":"video or image, markets","urlname":"novaremed","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$7mMbb1Fm7EizmLyKhodA8CZGMqisyEPxBjn7Wwnhem2Zx6SiraAfR8","name":"Novaremed","oneliner":"Medication for Chronic Neuropathic Pain","registrar":"514185891","website":"https://www.novaremed.com","careerspage":"","founded_month":9,"founded_year":2008,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/28642608","instagram":""},"social":["https://www.linkedin.com/company/28642608"],"flattenedsociallinks":"https://www.linkedin.com/company/28642608","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":10,"patent":1,"raised":67159176,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Novaremed, a privately held clinical-stage biopharmaceutical company, is developing effective and safe treatment options for managing chronic pain as an alternative to opioids.\r\n\r\nThe company's lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, FDA Fast Track Designation, and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy. \r\nThe earlier stage pipeline addressing chronic pain includes candidates MP-101 (Phase 2 stage), targeting prevention and treatment of chemotherapy-induced peripheral neuropathy; and MP-103 (preclinical stage). \r\nNovaremed's clinical development portfolio aims to satisfy high medical patient needs and societal demands by alleviating the burden of pain associated with diabetes and cancer for patients and countering over-reliance on addictive treatments.\r\n\r\nNovaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland).","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"9ed6c58c-c082-4866-a92c-8a72baf4e488","city":"Petah Tikva","type":null,"address":"HaSivim Street 24, Petah Tikva, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"70966859-84e0-4fc4-aca1-40b3cd786713","city":"Basel","address":"Teichgaesslein 9, 4058 Basel","country":"Switzerland","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"L8gHDDpxPES2SfaHRbbFMGUaQ4phEhbUvCwtpKzkD3cInSIcDWqCYY","date":"Jul 21, 2022","link":"https://www.businesswire.com/news/home/20220721005391/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"x6wHVfP2HF1HYJsyvfrhjPfG425DNpVBjEn2RDghDdqrMAKzL4D7P9","news_summary":"Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"wB3QKQzZDWjB7axoY8kMdHUPxhV5F1YGjAbScVUE3Mrk2LGaM2kqSr","date":"Jun 23, 2022","link":"https://www.businesswire.com/news/home/20220623005585/en/Novaremed-Announces-Publication-of-Phase-1-and-Phase-2a-Study-Data-With-NRD.E1-Demonstrating-the-Potential-of-This-Investigational-Non-opioid-Pain-Treatment","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"BfpkEfYX9fCNaiu1Xrsmkd8UwakXDwNVxgP3LBAkoVR4zsYXSLwZCK","news_summary":"Novaremed Announces Publication of Phase 1 and Phase 2a Study Data With NRD.E1 Demonstrating the Potential of This Investigational Non-opioid Pain Treatment","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"f78cca45-7033-4f51-b9ba-66e9803ff878","date":"Dec 29, 2021","link":"https://www.startupticker.ch/en/news/novaremed-s-lead-molecule-enters-phase2b-trials","source":"www.startupticker.ch","visible":1,"analysis":{"tags":"clinical trial","company":"Novaremed","layoffs":null,"summary":"The National Institutes of Health (NIH) will sponsor and conduct a clinical Phase 2b study with Novaremed’s lead non-opioid development compound NRD.E1 in the treatment of painful diabetic peripheral neuropathy (PDPN). The trial builds on Phase 2a proof-of-concept study in PDPN, which showed a clinically relevant reduction in patient-reported pain and good tolerability of NRD.E1.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["NIH","Phase 2b study","NRD.E1","painful diabetic peripheral neuropathy","clinical trial"],"date_of_event":"second quarter of 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"awOnLehgMjzfxmkeMuyAoQbnPhbu1in12datPqgYlS8ttdrIxJf7QD","news_summary":"Novaremed's lead molecule enters Phase2b trials","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AlUqz6YKmnFTaRAUgfHpqbb3S87Y6JN6ET4NbMryMRdl9uo3R8fWsY","date":"Sep 7, 2021","link":"https://www.businesswire.com/news/home/20210907005360/en/Novaremed-Expands-its-Pipeline-of-Non-opioid-Treatment-Candidates-for-Chronic-Pain-Indications-Through-Acquisition-of-Metys-Pharmaceuticals","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"RUUHAqzFET53wZWzePR9pq5ZrYfr9QwMnPxdKMN9XqD7Rrhf6Bi6jj","news_summary":"Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"dbacba6c-fce5-47a6-a104-20bfbb003f53","date":"Feb 4, 2021","link":"https://www.finsmes.com/2021/02/novaremed-secures-us50m.html","source":"www.finsmes.com","visible":1,"analysis":{"tags":"investment","company":"Novaremed","layoffs":null,"summary":"Novaremed, a clinical-stage biopharmaceutical company, has secured a US$50 million capital commitment from GEM Global Yield LLC SCS. The funding will be used to progress the clinical development of Novaremeds lead product for the treatment of painful diabetic peripheral neuropathy. Novaremed was founded in 2008 in Israel and aims to become a leader in innovative treatment options for chronic pain.","partners":null,"customers":null,"investors":"GEM Global Yield LLC SCS","confidence":9,"key_topics":["Novaremed","GEM Global Yield","capital commitment","share subscription facility","clinical development"],"date_of_event":"04/02/2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$50 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"c4VuT8cL1LoLKgaUtN8MHk7GNQtooKn4XznM0CjarWeQiDE42RklNx","news_summary":"Novaremed Secures US$50M - FinSMEs","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cda0ec10-4e62-4518-b1cd-06a69f3fa6b1","date":"Dec 18, 2020","link":"https://www.businesswire.com/news/home/20201218005198/en/Novaremed-Receives-Fast-Track-Designation-from-the-FDA-for-NRD135S.E1-for-the-Treatment-of-Painful-Diabetic-Peripheral-Neuropathy","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"yddRHzHGJqoITyAoayxHuxNQGlGjglGsU43vUWymnyrH0qD3dSeyyr","news_summary":"Novaremed Receives Fast Track Designation from the FDA for NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d5b1e6cb-d5a8-48a6-bbd9-2fd9ed524f38","date":"Sep 15, 2020","link":"https://www.biospace.com/article/releases/novaremed-announces-closing-of-a-new-financing-publication-of-pct-patent-application-and-participation-at-iasp-virtual-conference-on-pain-and-amp-expo/","source":"www.biospace.com","visible":1,"analysis":{"tags":"financing","company":"Novaremed AG","layoffs":null,"summary":"Novaremed AG has raised CHF2.5 million in an oversubscribed financing round, bringing the total financing raised by the company to CHF23.5 million. The funds will be used to prepare for a Phase 2b clinical study in the US for its drug candidate, NRD135S.E1, for the treatment of Painful Diabetic Peripheral Neuropathy. The company has also published a PCT patent application for a targeted therapy to treat pain and inflammation. Novaremed is participating in a virtual conference on pain and its Phase 2a study results have been accepted for the virtual poster gallery.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["financing","clinical study","drug candidate","patent application","conference"],"date_of_event":"2020-09-15","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"CHF2.5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xHx0Zkyxbxg35BhEA2qbf5SJJ9EN6CmZ90C6xrhE6oycA9JqxxW80z","news_summary":"Novaremed Announces Closing of a New Financing, Publication of PCT Patent Application and Participation at IASP Virtual Conference on Pain & Expo  BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6a607b44-a757-4c02-8962-78d28227b67e","date":"Jun 23, 2020","link":"https://www.businesswire.com/news/home/20200623005544/en/Novaremed-Announces-U.S.-FDA-Approval-of-IND-Application-to-Initiate-Phase-2-Clinical-Study-of-NRD135S.E1-for-the-Treatment-of-Painful-Diabetic-Peripheral-Neuropathy","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"nJf8Jk0bbu2fiA47gcLsxwaUVFFvrB4Ev7JJKuGGbWYL0Ju7HqeZrk","news_summary":"Novaremed Announces U.S. FDA Approval of IND Application to Initiate Phase 2 Clinical Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ca2d883a-c2d7-49fb-8731-3441e6f3d8e0","date":"Sep 2, 2019","link":"https://www.businesswire.com/news/home/20190902005074/en/Novaremed-Secures-Additional-Financing-Strengthens-Leadership","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"UGK0CTQTpz9reK1BvJf5dVQ4YtA6TmVDnw75RIisEXQEaonP0DkYHZ","news_summary":"Novaremed Secures Additional Financing and Strengthens Leadership","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"af02b071-2e0e-4bf1-840a-8742b956a805","date":"Jul 29, 2019","link":"https://www.businesswire.com/news/home/20190729005621/en/Novaremed-Announces-Management","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Management Changes","company":"Novaremed AG","layoffs":"N/A","summary":"Novaremed AG, a Swiss biopharmaceutical company, announced that Dr. Nicholas Draeger has decided to step down as CEO and member of the Board of Directors. He will serve as a senior advisor to Novaremed to ensure a smooth leadership transition. The search for a full-time successor to Dr. Draeger has been initiated. In the interim, Mr. Subhasis Roy, COO, and Dr. Sara Mangialaio, CMO and Head of R&D, will be assuming responsibilities for the company’s day to day operations and all clinical development work, respectively.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["CEO Resignation","Leadership Transition","COO","CMO","Clinical Development"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-negative","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"QJgTRULfmEBymXBpCTSVqXkb9HHtF2pO0mNk4GHV1JoiU5EtCiIeKR","news_summary":"Novaremed Announces Management Changes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3ec9143e-8652-4c55-8ff7-bb1ece10417a","date":"May 17, 2019","link":"https://www.biospace.com/article/releases/novaremed-presents-top-line-results-from-phase-2a-diabetic-neuropathic-pain-study-of-nrd-e1-at-neupsig-2019/","source":"www.biospace.com","visible":1,"analysis":{"tags":"clinical-stage biopharmaceutical","company":"Novaremed AG","layoffs":null,"summary":"Novaremed AG, a clinical-stage Swiss biopharmaceutical company, announced the top-line results from a Phase 2a study of NRD.E1 for the treatment of diabetic neuropathic pain. The study showed clinically relevant treatment benefits and provides a strong scientific foundation for the upcoming Phase 2b study. Novaremed is developing NRD.E1, an orally-active small molecule, and is preparing for a global Phase 2b study expected to start in Q4 2019.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Phase 2a study","NRD.E1","diabetic neuropathic pain","clinical trial results","upcoming Phase 2b study"],"date_of_event":"May 11, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pX1FBJClN1D3kQAG919QQb8iPAQsfqDZD08zCLWAHI9Lr6Fgx54m0C","news_summary":"Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 2019  BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"54502bcb-eeff-4c72-97d3-5e60218721ec","date":"Mar 5, 2019","link":"https://www.businesswire.com/news/home/20190305005776/en/Nicholas-Draeger-Named-New-CEO-Novaremed-AG","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"nXug7NVvP46QEi094gBr7GUJ6DKHIG8H8YA8ZRRSLhf16K3kX8udze","news_summary":"Nicholas Draeger Named New CEO of Novaremed AG","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"53e71696-795b-4053-a141-7b072243a8e9","date":"Oct 29, 2018","link":"https://www.startupticker.ch/en/news/october-2018/novaremed-closer-to-the-ambition","source":"www.startupticker.ch","visible":1,"analysis":{"tags":"clinical trials, diabetic neuropathic pain","company":"Novaremed AG","layoffs":null,"summary":"Novaremed AG, a clinical-stage biopharmaceutical company based in Basel, is preparing for global phase 2b clinical trials of its novel treatment for diabetic neuropathic pain. Diabetes is the leading cause of neuropathy, and a significant number of diabetic patients suffer from chronic, debilitating pain. Novaremeds lead compound, NRD.E1, has shown promising results in reducing patient-reported pain in a clinical study. To fund further studies, the company has raised CHF 6 million from existing shareholders and new private investors, in addition to the CHF 4.44 million raised earlier. The investment reflects the potential seen in Novaremed and its lead program in diabetic neuropathic pain.","partners":null,"customers":null,"investors":"existing shareholders, new private investors","confidence":9,"key_topics":["Novaremed AG","clinical trials","diabetic neuropathic pain","NRD.E1","investment"],"date_of_event":"Q4 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"CHF 6 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FJaDsvqUX3g37H1YVMZqONo7a3QdkPtQm161j3npugsnrhbS0qasX4","news_summary":"Novaremed gets closer to ambition","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"87fa920d-2fa9-494a-8e66-f46d1524f7f7","date":"Aug 23, 2018","link":"https://www.businesswire.com/news/home/20180823005596/en/Novaremed-announces-raised-CHF-6-million-prepare","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"O6GkwYrNfGapMeGlF6oc9lSGQy2xRIIFDYJ2iDNLyhy3SRogy93ewf","news_summary":"Novaremed announces that it has raised CHF 6 million to prepare for a Phase 2b clinical study in Diabetic Neuropathic Pain","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ec46689c-ec04-40fb-8f8d-3aac9cea9d25","date":"Aug 23, 2017","link":"https://www.openaccessgovernment.org/novaramed-novel-medication-neuropathic-pain/36429/","source":"www.openaccessgovernment.org","visible":1,"analysis":{"tags":"neuropathic pain","company":"Novaremed","layoffs":null,"summary":"Novaremed, an Israeli pharmaceutical company, is developing a treatment for neuropathic pain caused by nervous system damage. Neuropathic pain is a global health issue, and Novaremeds proposed treatment, NRD.E1, has the potential to bring relief to a large population suffering from this problem. The company successfully completed a phase 2a study in June 2016 and is now planning a phase 2b study to test the effectiveness of NRD.E1. If proven effective, this medical breakthrough could have a significant impact on the companys growth. The article highlights the rising incidences of neuropathic pain due to an aging population, diabetes, and shingles, and the high cost associated with chronic pain in the US.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["neuropathic pain","treatment","pharmaceutical company","NRD.E1","phase 2b study"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yENwg5fVWKZANrtowRkMcx6aEeLywixm5ohEqGDdLMtjOY06NpjaSf","news_summary":"Novaramed - Novel medication for neuropathic pain","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c9ff81c1-38cd-4bd6-9fa5-7b3acda1ec0f","date":"Jan 22, 2009","link":"http://www.globes.co.il/en/article-1000419305","source":"www.globes.co.il","visible":1,"analysis":{"tags":"investment","company":"Biomedix Incubator Ltd.","layoffs":null,"summary":"Biomedix Incubator Ltd.s subsidiary, Ashkelon Technological Industries, is investing NIS 2.38 million in start-up Novaremed Ltd. and will own 35% of the firm. The investment is partially funded by the Office of the Chief Scientist. Novaremed is developing NEB74S, a small molecule for chronic pain treatment. The chronic pain treatment market is expected to reach $24 billion in revenue by 2016.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Chronic pain treatment","Novaremed Ltd.","Ashkelon Technological Industries","Biomedix Incubator Ltd.","NEB74S"],"date_of_event":"January 22, 2009","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"NIS 2.38 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sVd6GDFe1rviioqT2B8obakUHHajZSRETMkyJvGVPgsLWSTFI5UWRz","news_summary":"Pain treatment co Novaremed joins Ashkelon incubator","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":16,"techcommunityinvolvement":null,"mediagallery":[],"tags":["pain-relief","pharmaceuticals","chronic-pain","diabetes","oral-drugs"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["NRD.E1"],"geomarkets":["Switzerland","United States","Europe"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":3,"lastfunding":"$50M","totalrounds":6,"fundingstage":"A","totalfunding":"$67.16M","publicinvestors":3,"lastpublicfunding":50000000,"totalpublicrounds":6,"totalpublicfunding":67159176},"team":[{"name":"Isaac Kobrin","email":"itzikkob@gmail.com","phone":"","gender":"Unknown","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkKzV8r0LDA","bounced":false,"claimed":1,"founder":0,"urlname":"isaac-kobrin","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQrPXOtAsM","position":"Executive Chairman of the Board of Directors","last_name":"Kobrin","claimtoken":"42e147427f192532a4110b567a627d3774efbb9c6cd261accd5ed6c5a064888b","first_name":"Isaac","picturekey":"$0JCHbUHVIAGGVOAv4gzP0cT6XAQDDDiIea8prFOfrZVftPz5CYOuMY","claimeddate":"2022-04-05","linkedinurl":"https://www.linkedin.com/in/isaac-kobrin-0a1aa15/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-04-05 15:08:42.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$0JCHbUHVIAGGVOAv4gzP0cT6XAQDDDiIea8prFOfrZVftPz5CYOuMY","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eliahu Kaplan, M.D.","email":"eliahu.kaplan@novaremed.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGywPMIDA","bounced":true,"claimed":0,"founder":1,"urlname":"eliahu-kaplan-md","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAsZeE8goM","position":"Founder & CEO","last_name":"Kaplan, M.D.","claimtoken":"R2JeTmx08vA1SvV3UnMD8EoQYkFheQ0GaeoJb2fF4jpfYpZgktXuJw","first_name":"Eliahu","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/eliahu-kaplan-81b247158/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-14 19:35:52.000000","initials":"EK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Maurizio  Rainisio","email":"maurizio.rainisio@novaremed.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4JbMlOkKDA","bounced":false,"claimed":0,"founder":0,"urlname":"maurizio-rainisio","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg5oHzrwkM","position":"Head of Biometry","last_name":"Rainisio","claimtoken":"dEUgQto0shpJi4vtfVoP0ZVLJAPyA1MLT8f64t2mR2xbfmLJjE0VOI","first_name":"Maurizio ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/maurizio-rainisio/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-14 19:36:25.000000","initials":"MR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Liat  Hochman, M.Sc.","email":"liat.hochman@novaremed.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLGDp7YIDA","bounced":false,"claimed":0,"founder":0,"urlname":"liat-hochman-msc","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAnt-ImAkM","position":"Head of Operations","last_name":"Hochman, M.Sc.","claimtoken":"hbWbMuCRoRmT97Id1aFWmrnnj4bK1ojX0KKm7BpQxPxsAFLlOKaI1L","first_name":"Liat ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/liat-hochman-3858bb184/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-14 19:35:37.000000","initials":"LH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgN7UwIEIDA","fullname":"Aviv Alper"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverifydate":"2020-02-10T00:00:00.000Z","crunchbaseid":"novaremed-ag","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yamila Silbert","creator_email":"yamila.urwicz@gmail.com","createdate":"2015-01-14T00:00:00.000Z","biverification":"Natalia Golczar","sectorverification":"Aviv Alper","affiliatedOrganizations":null,"timeline":[{"id":"1AysBqETdWKnq4OkMFXvUWxTPRlvYYj38xXCK7H5Dc7v5NYPNzgVuS","date":"Sep 2021","amount":"Undisclosed","source":"https://www.businesswire.com/news/home/20210907005360/en/Novaremed-Expands-its-Pipeline-of-Non-opioid-Treatment-Candidates-for-Chronic-Pain-Indications-Through-Acquisition-of-Metys-Pharmaceuticals","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Metys Pharmaceuticals","acquiredcompany_mna_id":"cpWn0bifel0RUxPO0CYd0C9EHRfZbIrZ6iP8nrHAEWS3YMgvq2y7nE","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/metys-pharmaceuticals","acquiredcompany_mna_logokey":"$G25eZLwRtKqzyCZ4Th0NnlOVpd04YOhpnrIUhk1iG7HhfYR5wpkq5c","acquiredcompany_mna_urlname":"/company_page/metys-pharmaceuticals","acquiredcompany_mna_homepage":null,"style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$G25eZLwRtKqzyCZ4Th0NnlOVpd04YOhpnrIUhk1iG7HhfYR5wpkq5c","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODn29qyCAw","date":"Feb 2021","amount":"$50M","source":"https://www.finsmes.com/2021/02/novaremed-secures-us50m.html","eventtype":"FundingRoundEvent","investment":[{"name":"GEM Global Yield LLC","type":"Investor","amount":50000000,"hidden":false,"country":"Luxembourg","fullurl":"/investor_page/gem-global-yield-llc","logokey":null,"tagline":"","urlname":"/investor_page/gem-global-yield-llc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODn9M6CCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0d1798ae-bca3-4363-abac-8479dc1d854b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":50000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODNsMKZCww","date":"Sep 2020","amount":"$2.7M","source":"https://www.novaremed.com/news/novaremed-announces-closing-of-a-new-financing-publication-of-pct-patent-application-and-participation-at-iasp-virtual-conference-on-pain-expo/","eventtype":"FundingRoundEvent","investment":[{"name":"Shareholders","type":"Other","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/shareholders","logokey":null,"tagline":"","urlname":"/company_page/shareholders","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODEleuTCgw","fundingtype":"Other","leadpartner":null,"investmentid":"72318f3d-b141-4a1b-8511-f8d6b5a8c96e","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCW26jdCww","date":"Sep 2019","amount":"$2.66M","source":"https://www.businesswire.com/news/home/20190902005074/en/Novaremed-Secures-Additional-Financing-Strengthens-Leadership","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"958ed4e1-0492-44db-b920-766e9438a4a9","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2659176,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkidqICAw","date":"Aug 2018","amount":"$6M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEv960CAw","date":"Apr 2018","amount":"$4.5M","source":"https://www.novaremed.com/news/novaremed-announces-that-it-has-raised-chf-4-4-million/","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":4500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko46rCQw","date":"Nov 2008","amount":"$1.3M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"9/2008","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Novaremed","logourl":"https://storage.googleapis.com/clean-finder-353810/$7mMbb1Fm7EizmLyKhodA8CZGMqisyEPxBjn7Wwnhem2Zx6SiraAfR8","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$7mMbb1Fm7EizmLyKhodA8CZGMqisyEPxBjn7Wwnhem2Zx6SiraAfR8","seoabout":"Novaremed, a privately held clinical-stage biopharmaceutical company, is developing effective and safe treatment options for managing chronic pain as an al...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODn29qyCAw","date":"Feb 2021","amount":"$50M","source":"https://www.finsmes.com/2021/02/novaremed-secures-us50m.html","eventtype":"FundingRoundEvent","investment":[{"name":"GEM Global Yield LLC","type":"Investor","amount":50000000,"hidden":false,"country":"Luxembourg","fullurl":"/investor_page/gem-global-yield-llc","logokey":null,"tagline":"","urlname":"/investor_page/gem-global-yield-llc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODn9M6CCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0d1798ae-bca3-4363-abac-8479dc1d854b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":50000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODNsMKZCww","date":"Sep 2020","amount":"$2.7M","source":"https://www.novaremed.com/news/novaremed-announces-closing-of-a-new-financing-publication-of-pct-patent-application-and-participation-at-iasp-virtual-conference-on-pain-expo/","eventtype":"FundingRoundEvent","investment":[{"name":"Shareholders","type":"Other","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/shareholders","logokey":null,"tagline":"","urlname":"/company_page/shareholders","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODEleuTCgw","fundingtype":"Other","leadpartner":null,"investmentid":"72318f3d-b141-4a1b-8511-f8d6b5a8c96e","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCW26jdCww","date":"Sep 2019","amount":"$2.66M","source":"https://www.businesswire.com/news/home/20190902005074/en/Novaremed-Secures-Additional-Financing-Strengthens-Leadership","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"958ed4e1-0492-44db-b920-766e9438a4a9","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2659176,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkidqICAw","date":"Aug 2018","amount":"$6M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEv960CAw","date":"Apr 2018","amount":"$4.5M","source":"https://www.novaremed.com/news/novaremed-announces-that-it-has-raised-chf-4-4-million/","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":4500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko46rCQw","date":"Nov 2008","amount":"$1.3M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[{"id":"1AysBqETdWKnq4OkMFXvUWxTPRlvYYj38xXCK7H5Dc7v5NYPNzgVuS","date":"Sep 2021","amount":"Undisclosed","source":"https://www.businesswire.com/news/home/20210907005360/en/Novaremed-Expands-its-Pipeline-of-Non-opioid-Treatment-Candidates-for-Chronic-Pain-Indications-Through-Acquisition-of-Metys-Pharmaceuticals","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Metys Pharmaceuticals","acquiredcompany_mna_id":"cpWn0bifel0RUxPO0CYd0C9EHRfZbIrZ6iP8nrHAEWS3YMgvq2y7nE","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/metys-pharmaceuticals","acquiredcompany_mna_logokey":"$G25eZLwRtKqzyCZ4Th0NnlOVpd04YOhpnrIUhk1iG7HhfYR5wpkq5c","acquiredcompany_mna_urlname":"/company_page/metys-pharmaceuticals","acquiredcompany_mna_homepage":null,"style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$G25eZLwRtKqzyCZ4Th0NnlOVpd04YOhpnrIUhk1iG7HhfYR5wpkq5c","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}